FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 701 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of... March 10, 2023 Home Is Where the Heart Is November 8, 2019 Nanoparticle Trains Immune Cells to Attack Cancer December 4, 2020 Load more HOT NEWS Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... Struggling Waitress Who Can’t Feed Her 4 Kids After Husband’s Cancer... EMA Recommends Granting a Marketing Authorisation for Tarlatamab Death Rates from Lung Cancer will Fall Overall in the EU...
